Keyphrases
Murine Model
100%
PARP Inhibitor (PARPi)
100%
Beneficial Effects
100%
Doxorubicin
100%
Heart Failure
100%
Poly (ADP-ribose) Polymerase Inhibition
80%
Chronic Heart Failure
60%
Cardiac Function
40%
Cardiac Dysfunction
40%
Vascular Relaxation
40%
INO-1001
40%
Aortic Rings
20%
Oxidative Stress
20%
Tissue Injury
20%
Endotoxin
20%
Poly(ADP-ribose) Polymerase
20%
Nitrosative Stress
20%
Rat Model
20%
Mouse Model
20%
Left Ventricular Function
20%
Experimental Therapeutics
20%
Endothelial Dysfunction
20%
Left Anterior Descending Coronary Artery
20%
Heart Transplantation
20%
Myocardial Ischemia-reperfusion Injury
20%
Overactivation
20%
Cell Dysfunction
20%
Diabetic Cardiomyopathy
20%
Pathophysiological Conditions
20%
Myocardial Contraction
20%
Cardiac Output
20%
Multiple Injections
20%
Ejection Fraction
20%
Effective Approach
20%
High Mortality
20%
Endotoxin Model
20%
Stroke Work
20%
Antitumor Effect
20%
Stroke Volume
20%
Acute Heart Failure
20%
Acute Myocardial Dysfunction
20%
Advanced Aging
20%
Coronary Ligation
20%
Endothelial Remodeling
20%
Bacterial Endotoxin
20%
Induced Mortality
20%
Aortic Banding
20%
Left Ventricular End-diastolic Pressure
20%
Permanent Ligation
20%
Medicine and Dentistry
PARP Inhibitor
100%
Heart Failure
100%
Poly ADP Ribose Polymerase
71%
Doxorubicin
71%
Endotoxin
42%
Heart Function
28%
Oxidative Stress
14%
Tissue Injury
14%
Heart Left Ventricle Performance
14%
Left Anterior Descending Coronary Artery
14%
Apoplexy
14%
Experimental Therapy
14%
Endothelial Dysfunction
14%
Myocardial Ischemia Reperfusion Injury
14%
Heart Transplantation
14%
Ligation
14%
Heart Output
14%
Systolic Blood Pressure
14%
Ejection Fraction
14%
Nitrosative Stress
14%
Diabetic Cardiomyopathy
14%
Stroke Volume
14%
Coronary Artery Ligation
14%
Heart Muscle Contractility
14%
Acute Decompensated Heart Failure
14%
Pharmacology, Toxicology and Pharmaceutical Science
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
100%
Heart Failure
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
71%
Doxorubicin
71%
Endotoxin
42%
Tissue Injury
14%
Mouse Model
14%
Rat Model
14%
Endothelial Dysfunction
14%
Myocardial Ischemia Reperfusion Injury
14%
Diabetic Cardiomyopathy
14%
Acute Heart Failure
14%